AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD

Allergan plc

Clonshaugh Business and Technology Park
Coolock
Dublin D17 E400
Ireland

http://www.allergan.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees16,900

Key Executives

NameTitlePayExercisedYear Born
Mr. Brenton L. SaundersChairman, Pres & CEO4.48MN/A1970
Mr. Matthew M. WalshExec. VP & CFO9.84MN/A1967
Mr. A. Robert D. BaileyExec. VP, Chief Legal Officer & Corp. Sec.2.35MN/A1963
Mr. William MeuryExec. VP & Chief Commercial Officer3.03M4.06M1968
Dr. C. David NicholsonExec. VP and Chief R&D Officer2.59MN/A1955
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has a collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and gene therapy research collaboration with The National Institute for Bioprocessing Research and Training. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Corporate Governance

Allergan plc’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.